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Abstract
There is increasing evidence indicating a role for Fusobacterium nucleatum (F. nucleatum) in colorectal cancer (CRC) development and
prognosis. This study evaluatedF. nucleatum as a prognostic biomarker, by assessing its association with post-diagnosis survival fromCRC.
FromSeptember2008 toApril2012CRCpatients (n=190)were recruited fromthreehospitalswithin theCzechRepublic.F.nucleatumDNA
copiesweremeasuredinadjacentnon-malignantandcolorectal tumor tissuesusingquantitativereal-timePCR.CoxProportionalHazards(HR)
modelswereapplied toevaluate theassociationbetweenF.nucleatumDNAandoverall survival,adjustingforkeyconfounders.Riskprediction
modelingwasconductedtoevaluate theability topredictsurvivalbasedonF.nucleatumstatus.High,comparedwithlow, levelsofF.nucleatum
incolorectaltumortissueswereassociatedwithpooreroverallsurvival(adjustedHR1.68,95%CI1.02–2.77),whichwasslightlyattenuatedafter
additionaladjustmentformicrosatelliteinstabilitystatus.However, inclusionofF.nucleatum inriskpredictionmodelsdidnotimprovetheability
to identify patients who died beyond known prognostic factors such as disease pathology staging. Although the increased presence of
F. nucleatumwas associatedwith poorer prognosis inCRCpatients, thismayhave limited clinical relevance as a prognostic biomarker.
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Introduction
Accumulating evidence indicates a potential association
of microbiome dysbiosis with colorectal cancer (CRC)
development and prognosis [1, 2].
Fusobacterium nucleatum (F. nucleatum) is an anaero-
bic, gram-negative commensal pathogen that is associated
with several human diseases, especially those related to
the oral and intestinal tract [3, 4]. Numerous studies have
shown higher abundance of F. nucleatum DNA or RNA in
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CRC tumors versus surrounding non-malignant mucosa,
or in stool sample DNA from CRC patients compared
to controls [5–12] (reviewed in [13]). These findings are
consistent with in vitro and animal model evidence and
human studies indicat ing an et iological role of
F. nucleatum in colorectal carcinogenesis through promo-
tion of an immunocompromised proinflammatory micro-
environment favorable to tumor initiation and progression
[5, 14–17]. Alternatively, growth of F. nucleatum may
simply reflect an opportunistic invader capable of surviv-
ing the harsh hypoxic conditions of developing tumors
[8].
Regarding CRC pathology and clinical characteristics,
high levels of F. nucleatum in stool and tumor tissue have
been associated with right-sided tumors, higher stage, mo-
lecular subtypes, and worse clinical outcome (reviewed in
[7, 18–20]). Several studies in diverse geographical set-
tings, following the initial observation by Flanagan et al.
(2014) [11], suggest that F. nucleatum may affect clinical
outcome for CRC patients. These studies observed that
higher tumor F. nucleatum levels were associated with
poorer overall survival (OS) in CRC patients from the
Czech Republic, China, Japan [11, 21–23], and metastatic
CRC in South Korea [24]. The Chinese study from Wei
et al. also reported an association with lower disease-free
survival (DFS) [22]. Although a US study reported no
association between high tumor F. nucleatum levels and
OS in a large cohort of CRC patients, they did observe an
association with shorter CRC-specific survival indepen-
dent of clinical, pathological, and tumor molecular char-
acteristics [25].
However, given the limited number of published studies to
date, there is a need to further examine the relationship between
F. nucleatum and CRC prognosis, and to what extent measure-
ment ofF. nucleatumDNAmay serve as a prognostic biomarker.
The aims of this study were to assess the association between
F. nucleatum DNA levels from tumor and adjacent non-
malignant tissue with survival outcomes in a much larger and
separate cohort of 190 Czech patients with CRC to our initial
study suggesting a link with poorer overall patient survival [11].
Materials and methods
Study population
This cohort study included 190 adult patients diagnosed
with histologically confirmed CRC. All subjects were re-
cruited from September 2008 to April 2012 from one of
three hospitals in the Czech Republic (General University
Hospital, Thomayer Hospital in Prague and Biomedical
Centre, Faculty of Medicine in Pilsen). Table 1 lists the
participant characteristics.
Data collection and follow-up
A structured questionnaire assessed patients’ personal charac-
teristics (either self-reported or through interviews with their
doctors), including date of birth, sex, lifestyle habits, body
mass index (BMI), diabetes, and personal/family history of
cancer. Clinicians recorded information about tumor location,
tumor-node-metastasis (TNM) stage system, degree of tumor
differentiation, and adjuvant chemotherapy treatment details.
Patients with Lynch syndrome, polyposis syndromes, inflam-
matory bowel disease, or incomplete information on baseline
characteristics were excluded. Follow-up information about
distant metastasis, relapse, and date of death was also recorded
and all registered patients were followed from surgery to death
or to the end of the study (September 2018).
DNA extraction
After surgical resection, colorectal tumor and adjacent non-
malignant tissue samples were freshly frozen and conserved in
either liquid nitrogen or RNA later and stored at − 80 °C.
DNAwas extracted from colorectal and adjacent tissues using
the DNeasy Blood and Tissue Kit and by following the man-
ufacturer’s instructions (Qiagen, Courtaboeuf, France). The
DNA concentration was determined using the Quant-IT
dsDNA BR Assay Kit (Life Technologies Czech Republic
s.r.o., Prague, Czech Republic) and an Infinite M200 fluores-
cence reader (Tecan Group Ltd., Männedorf, Austria).
Microsatellite instability (MSI) status was determined in tu-
mor tissue and non-malignant adjacent mucosa using a
pentaplex PCR assay of 5 mononucleotide repeat markers
(BAT25, BAT26, NR21, NR24, NR27) with fluorescently la-
beled primers and standard PCR chemistry [26]. Fragment
analysis was performer on ABI 3130 (Applied Biosystems,
Foster City, CA, USA). The final comparison between tumor
and non-tumor DNA short tandem repeat profiles was per-
formed with GeneMapper v4.1 software (Applied
Biosystems, Foster City, CA, USA). A tumor specimen was
classified as MSI-high when 2 or more loci were unstable
[26]. Mutation analysis for BRAF, KRAS, NRAS, and
PIK3CA was performed using a Randox mutation biochip
array (Randox Laboratories Ltd., Crumlin, Northern Ireland)
according to the manufacturer’s instructions, as previously
described [27].
Quantitative real-time polymerase chain reaction
Quantitative real-time polymerase chain reaction (qPCR)
measured the number of copies of F. nucleatum DNA (nusG
gene), and a control human prostaglandin transporter (PGT)
gene, in the colorectal tumor and non-malignant adjacent tis-
sue using an Applied Biosystems 7500 Real-Time PCR
System Levels, as previously detailed [11]. qPCR assays for
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Table 1 Participant characteristics in a cohort of 190 colorectal cancer patients based on F. nucleatum DNA status in colorectal cancer tissue
Low tumor F. nucleatum1 High tumor F. nucleatum2 P value
No. % No. %
Total 129 (68.2) 61 (31.8)
Age at surgery
Under 60 22 (17.1) 9 (14.8) 0.95
60–< 70 51 (39.5) 23 (37.7)
70–< 80 36 (27.9) 19 (31.1)
80+ 20 (15.5) 10 (16.4)
Sex
Female 40 (31) 20 (32.8) 0.81
Male 89 (69) 41 (67.2)
Tumor stage
I 25 (19.4) 9 (14.8) 0.238
II 36 (27.9) 23 (37.7)
III 44 (34.1) 14 (23)
IV 22 (17.1) 14 (23)
Unknown 2 (1.6) 1 (1.6)
Tumor location
Proximal colon 39 (30.2) 22 (36.1) 0.58
Distal colon 38 (29.5) 14 (23)
Rectal 52 (40.3) 25 (41)
Neo/adjuvant treatment3
No 89 (69) 34 (55.7) 0.07
Yes 40 (31) 27 (44.3)
Smoking history
Never 48 (43.6) 24 (45.3) 0.84
Ever 62 (56.4) 29 (54.7)
Missing 19 (14.5) 8 (13.1)
Body Mass Index
18.5–< 25 49 (38) 18 (29.5) 0.61
25–< 30 39 (30.2) 21 (34.4)
30+ 16 (12.4) 7 (11.5)
Missing 25 (19.4) 15 (24.6)
F. nucleatum DNA in non-malignant, adjacent tissue
Low1 117 (90.7) 36 (59.0)
High2 10 (7.8) 24 (39.3) < 0.001
Missing 2 (1.6) 1 (1.6)
Microsatellite instability status
MSS/MSI-L 105 (81.4) 40 (65.6)
MSI-H 3 (2.3) 10 (16.4) < 0.001
Missing 21 (16.3) 11 (18.0)
KRAS status
Wild type 57 (44.2) 18 (29.5)
Mutated 30 (23.3) 17 (27.9) 0.15
Missing 42 (32.6) 26 (42.6)
NRAS status
Wild type 80 (62.0) 34 (55.7)
Mutated 7 (5.4) 1 (1.6) 0.30
Missing 42 (32.6) 26 (42.6)
BRAF status
Wild type 81 (62.8) 31 (50.8)
Mutated 6 (4.7) 4 (6.6) 0.41
Missing 42 (32.6) 26 (42.6)
PIK3CA status
Wild type 78 (60.5) 31 (50.8)
Mutated 9 (7.0) 4 (6.6) 0.86
Missing 42 (32.6) 26 (42.6)
1 No F. nucleatum DNA detected within 42 PCR cycles or F. nucleatum (2−ΔCT ) below 0.0008 (i.e., the median among individuals with tumor
F. nucleatum DNA detected in 42 PCR cycles)
2F. nucleatum (2−ΔCT ) above 0.0008
3Neo-adjuvant or adjuvant radiotherapy or chemotherapy within 6 months of surgery
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F. nucleatum were performed in duplicate for each sample,
and a cutoff level of 42 replication cycles (cycle threshold;
CT) for both duplicate reactions was used to determine pres-
ence of F. nucleatum DNA. Bacterial abundance was calcu-
lated in both colorectal tumor tissue and adjacent tissue by
2−ΔCT, where ΔCT is the difference in the CT number for
F. nucleatum and the PGT reference gene assay.
F. nucleatum abundance (in individuals with the bacterium
detected) was divided into low and high groups based on
values below or above the median value, respectively.
Statistical analysis
All statistical analyses were performed using Stata version 14
(StataCorp, College Station, TX, USA).
The characteristics of patients based on the prevalence of
F. nucleatum were compared using chi-squared tests. Kaplan-
Meier curves and Cox Proportional Hazards ratio (HR)
models with 95% confidence intervals (95% CI) were applied
to evaluate the association between F. nucleatum in colorectal
tissue and overall survival. Both univariate and multivariate
analyses were conducted, adjusted for important confounders
such as age, sex, tumor stage, and chemotherapy or
radiotherapy.
Sensitivity analyses assessed whether the association
remained when conducting complete case analysis and sepa-
rately when excluding deaths within the first 6 months.
Further models included additional potential confounders as-
sociated with a 10% change in coefficient between
F. nucleatum and OS, when added individually to the main
multivariate model. The factors tested for inclusion were mo-
lecular characteristics (MSI status, mutations for BRAF,
KRAS, NRAS, and PIK3CA) and lifestyle factors (including
BMI and smoking history), tumor location, and the presence
of F. nucleatum in adjacent non-malignant tissue. MSI status
and F. nucleatum in adjacent non-malignant tissue were se-
lected as additional covariates. Continuous and tertile catego-
ry analyses were also conducted for assessing both
F. nucleatum tumor abundance (2−ΔCT) and bacterial quantifi-
cation in disease tissue over adjacent-matched colorectal tis-
sue (2−ΔΔCT). The three categories included “no/low,” where
values of F. nucleatum were not detectable or if the quantifi-
cation was in the lowest tertile group; “moderate” if bacterial
abundance was in the middle tertile category; or “high” if
F. nucleatum quantification was in the highest tertile rank.
In subgroup analyses, likelihood ratio tests assessed wheth-
er the association differed by age, sex, tumor stage, tumor
location, chemotherapy or radiotherapy, smoking history,
BMI, or by molecular characteristics (including status of
MSI, BRAF, KRAS, NRAS, and PIK3CA).
The use of F. nucleatum load as a prognostic marker
was examined by assessing the area under the receiver
operating characteristics (ROC) curve of existing
prognostic markers (tumor stage, age, sex, cancer treat-
ment, and MSI status) when including and excluding
tumor F. nucleatum status (high versus low).
Results
This study included 190 CRC patients who were followed up
for a median of 2.34 years (range 0.01–6.77), during which
time 71 patients died.
As observed in several studies [13], F. nucleatum was sig-
nificantly more abundant in the tumor tissue compared to the
matched surrounding mucosa (p = 0.002). Table 1 outlines the
participant characteristics according to the abundance of
F. nucleatum in CRC tumor tissue. One third of CRC patients
had high F. nucleatum abundance in their tumor tissue.
Patients with low and high abundance of F. nucleatum were
similar in terms of age, sex, tumor stage and location, neo-
adjuvant treatment receipt, smoking history, and BMI.
Patients with high tumor F. nucleatum were more likely to
have MSI tumors than patients with low tumor F. nucleatum
and tended to have a higher abundance of F. nucleatum in the
adjacent-matched non-malignant tissue.
The association between tumor F. nucleatum status and
overall survival is displayed in Table 2 and Fig. 1. There
was no association with survival in the unadjusted analyses.
However, high F. nucleatum was associated with poorer OS
compared to low levels of the bacterium in colorectal tissue in
fully adjusted models (HR 1.68, 95% CI 1.02–2.77, p = 0.04).
Further adjustment for MSI status and F. nucleatum abun-
dance in adjacent normal tissue did not markedly change this
result, although it did lose statistical significance (HR 1.80,
95% CI 0.97–3.28, p = 0.06; see Supplementary Table 1).
Additional factors considered in the adjustment model, com-
prising tumor colorectal subsite location, smoking history,
BMI, and mutations of KRAS, NRAS, BRAF, and PIK3CA,
did not meet the 10% change in coefficient criteria for con-
founder selection.
Sensitivity analyses for whether the association remained
when conducting complete case analysis or after excluding
deaths within the first 6 months did not substantially change
the HR estimates, although the latter lost significance (HR
1.71, 95% CI 0.94–3.10; Supplementary Table 1). No associ-
ations between tumor F. nucleatum status and OS were ob-
served when analyses were stratified by CRC molecular sub-
types (including BRAF, KRAS, NRAS, and PIK3CA mutation
status) (Supplementary Table 1). The association between
F. nucleatum and survival was significant in patients aged over
70 years old (HR 2.23, 95% CI 1.15–4.35, p = 0.02), in pa-
tients with left-sided tumors (HR 2.34, 95%CI 1.25–4.37, p =
0.008), and in those patients not receiving chemotherapy and/
or radiotherapy (HR 1.87, 95% CI 1.02–3.45, p = 0.04).
However, formal tests for statistical interaction were not
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significant. Other clinical factors such as smoking status did
not significantly modify the associations observed between
F. nucleatum and OS (Supplementary Table 1).
Considering bacterial presence in the surrounding non-
malignant mucosal tissue, a multivariate analysis using rela-
tive quantification of F. nucleatum (from the mucosal and
tumor levels) showed no association with OS (HR 1.04,
95% CI 0.62–1.76; Supplementary Table 1). However, tumor
levels adjusted for the corresponding F. nucleatum levels in
the surrounding mucosal tissue (and the main confounders)
were associated with poorer OS (HR 1.94, 95% CI 1.09–
3.46; Supplementary Table 1).
Assessing F. nucleatum levels in a continuous model pro-
vided null results (HR 1.00, 95% CI 0.99–1.00). We were
underpowered to conduct a restricted cubic spline analysis to
explore the curve for the continuous model. However, al-
though they were not significant, categorical analyses of no/
low, moderate, or high bacterial levels interestingly suggest
that this is largely due to a non-linear relationship where CRC
cases with moderate F. nucleatum have possibly better or
equivalent survival than those with no/low F. nucleatum in
their tumor tissues (see Supplementary Table 2). Survival then
decreases with higher bacterial load, as also indicated by the
Kaplan-Meier survival curves in our prior report from 2014
(see figure 3, Flanagan et al., 2014 [11]). Alternatively, this
may simply reflect lower power for these tertile groupings.
Repeating these categorical analyses by the delta-delta Ct
method used in Flanagan et al. [11] for comparing differences
in bacterial levels between tumor and matched mucosal tis-
sues, or by adjusting for F. nucleatum mucosal tissue levels,
made no major differences to the results (Supplementary
Table 2).
Finally, when the utility of F. nucleatum as a prognostic
marker was assessed by ROC curves, there was no improve-
ment in the area under the curve when added to traditional
prognostic markers or data such as tumor stage, age, sex,
treatment, and MSI status (Table 3).
Discussion
In this study, we found that high F. nucleatum DNA in colo-
rectal tumor tissue is associated with shorter survival in a
cohort of CRC patients from the Czech Republic. However,
prognostic modeling revealed that F. nucleatum may not lead
to notable improvements in our ability to predict patient prog-
nosis beyond other known indicators, such as tumor stage.
The association of higher levels of F. nucleatum
DNA with a shorter survival in CRC patients is concor-
dant with previous reports [11, 21–25]. These include
our initial study suggesting this link for the first time,
although in a small, separate group of 32 Czech CRC
patients giving imprecise HR estimates with wide con-
fidence intervals [11]. The large study by Mima et al.,
of tissue from 1069 CRC cases within the Nurses’
Health Study and the Health Professionals Follow-Up
study, found that high F. nucleatum was more strongly
associated with CRC-specific survival (HR 1.58, 95%
CI 1.04–2.39) than with OS (HR 1.08, 95% CI 0.76–
1.52) [25]. Given the long duration of follow-up in this
study (median of 10.7 years), analyses of OS under-
standably incorporated a high proportion of non-CRC
deaths (46%), likely underlying the null association with
OS for F. nucleatum. Considering the other two of these
reports which calculated HR values, then the strength of
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Fig. 1 Kaplan-Meier curve showing the overall survival of colorectal
cancer patients by the amount of F. nucleatum DNA in colorectal tumor
tissue (2−ΔCT); continuous line indicates low tumor F. nucleatum; broken
line indicates high tumor F. nucleatum. In the adjusted models, high
F. nucleatum was associated with poorer OS compared to lower levels
(HR 1.68, 95% CI 1.02–2.77, p = 0.04)
Table 2 Cox Proportional Hazards models for the association between Fusobacterium nucleatumDNA in colorectal cancer tissue and overall survival
F. nucleatum DNA in colorectal cancer tissue (2−ΔCT) Person-years No. of events Unadjusted Adjusted1
HR (95% CI) p value HR (95% CI) p value
Low/no 376.2 44 1.00 (referent) – 1.00 (referent) –
High 156.0 27 1.37 (0.85–2.22) 0.20 1.68 (1.02–2.77) 0.04
1Adjusted for age (< 60, 60–< 70, 70–< 80, 80+), sex (men, women), tumor stage (I, II, III, IV, missing), and chemotherapy or radiotherapy within
6 months (no, yes)
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the association for higher F. nucleatum with worse OS
seen in the current study (HR 1.68, 95% CI 1.02–2.77)
is similar to Chinese CRC patients (multivariate HR
1.99, 95% CI 1.02–3.88) [22] and very close to the
estimate for a South Korean metastatic CRC cohort
(multivariate HR 1.69, 95% CI 1.04–2.75) [24].
Therefore, the current study provides additional support that
F. nucleatum is independently associated with poorer OS for
CRC patients. Contrastingly, a recent and separate South
Korean study reported no association of bacterial levels with
survival for 593 stage II (high-risk) and stage III CRC patients
whom had all received oxaliplatin-based adjuvant chemotherapy
[28]. This aligns with our observation of no association between
F. nucleatum andOS in patients who had received chemotherapy
or radiotherapy. Furthermore, in subgroup analyses, these authors
also reported that higher F. nucleatum showed a non-significant
tendency toward worse prognosis in sigmoid colon and rectal
cancer but was significantly associated with a more favorable
DFS for non-sigmoid colon cancer patients that were also non-
MSI-high (i.e., MSS/MSI-low).We observed that the association
of higher bacterial levels with worse prognosis was more appar-
ent in patients with left-sided tumors (thus including sigmoid and
rectal cancers, as well as the splenic flexure and descending
colon). However, this Korean study was likely seriously con-
founded by study design and methodology issues such as the
lack of qPCR data on adjacent-matched tissues for each tumor,
and that FFPE tissue-derived DNA was used to estimate the
bacterial load resulting in a high number of failed PCRs for the
PGT control (21%) so that the results are possibly unreliable.
Indeed, tissue fixation method and storage time has been shown
to affect F. nucleatum qPCR positivity [24, 28].
The biological mechanism for the association between
F. nucleatum and patient survival has not been fully elucidat-
ed. The bacterium has been shown to persist in cancer cells
frommetastatic CRC lesions and Fusobacterium–culture pos-
itive tumors resulted in more successful xenografts in mice,
suggesting an association with more severe disease [29].
Human and functional studies provide evidence that
F. nucleatum–mediated increased gut inflammation and
chemoresistance, through immune signaling and autophagy
activation, largely explains the poorer prognosis for CRC pa-
tients [22, 30]. F. nucleatum may invade into tumor cells and
exacerbate inflammatory and oncogenic responses via FadA
adhesion to E-cadherin with beta-catenin pathway activation
[5] and through Fap2 binding of the Gal-GalNAc polysaccha-
ride overexpressed by CRC cells [15]. Additionally, Fap2 in-
teraction with the TIGIT receptor expressed on natural killer
cells may enhance immune evasion [17]. The bacterium is
also associated with upregulation of several inflammatory cy-
tokines through a postulated miRNA-mediated activation of
TLR2/TLR4 [31] and activation of the JAK/STAT and
MAPK/ERK pathways linked to CRC tumor progression
[32]. Alternatively, as in the case for any role in initial colo-
rectal carcinogenesis, F. nucleatum may not directly affect
CRC disease severity, but simply thrive in the increasingly
hostile tumor microenvironment of aggressive tumors that
are likely to be associated with a poorer prognosis. In contrast
to the suggested role of chemoresistance, in subgroup analy-
ses, we only observed an association between higher
F. nucleatum and OS in patients who did not receive chemo-
therapy or radiotherapy. However, our power was very limited
to adequately evaluate this due to low numbers of patients
with both high bacterial levels and relevant therapy data, and
formal tests for statistical interaction were not significant.
Further analyses by continuous or category (no/low, moderate,
and high) levels of F. nucleatum possibly suggest that moder-
ate amounts may be conversely associated with better or equal
survival than for patients with no/low presence of the bacteri-
um in their tumor tissue. Conceivably, this could be through
triggering of an increased immune response that may combat
tumor progression/recurrence until the bacterium reaches
higher amounts that would compromise therapy and/or make
the cancer more aggressive. Alternatively, this may again re-
flect a non-causative correlation between higher bacterial
Table 3 Performance of
prognostic models for five-year
overall survival in colorectal
cancer patients when including
and excluding tumorF. nucleatum
status
AUROC (95% CI)
Tumor stage 0.68 (0.60–0.76)
Tumor stage + F. nucleatum 0.69 (0.61–0.77)
Age, sex, tumor stage 0.78 (0.72–0.85)
Age, sex, tumor stage + F. nucleatum 0.78 (0.71–0.85)
Age, sex, tumor stage, treatment 0.78 (0.71–0.84)
Age, sex, tumor stage, treatment + F. nucleatum 0.78 (0.71–0.84)
Age, sex, tumor stage, treatment, and MSI status 0.83 (0.77–0.89)
Age, sex, tumor stage, treatment, and MSI status + F. nucleatum 0.83 (0.77–0.89)
F. nucleatum, Fusobacterium nucleatum; AUROC, area under receiver operating characteristic curve, 95% CI,
95% confidence intervals; MSI, microsatellite instability
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levels in more severe cancers. Although, considerable caution
is required in assessing these results, as none were significant
and there was lower power for these evaluations.
In analyses by CRC molecular subtypes, we found that the
association between F. nucleatum and overall survival was no
longer statistically significant after additional adjustment forMSI
status and presence of the bacterium in adjacent non-malignant
tissue. This may be attributable to low statistical power, as few
individuals wereMSI-high (n = 13). Stratified analysis in patients
with MSI-low/stable colorectal tumors, or by BRAF, KRAS,
NRAS, and PIK3CA mutation status, also showed no evidence
of an association between F. nucleatum and OS. Unfortunately,
we had insufficient statistical power to conduct this analysis for
MSI-high tumors. Nonetheless, a strong association between the
amount of F. nucleatum in CRC tissue and MSI-high was ob-
served in the study by Mima et al. [25]. Although MSI-high
status is generally perceived as a favorable prognostic indicator,
a large cohort study of Stage II/III colon cancer patients from
Northern Ireland defined a subgroup of patients havingMSI-high
tumors with a high fibroinflammatory score that were associated
with a 2.5-fold increased risk of death [33]. The
fibroinflammatory score is indicative of tumor microenviron-
ment features such as peritumoral diffuse lymphoid inflamma-
tion, Crohn’s disease-like reaction, and tumor stromal propor-
tions [33]. However, as we were unable to measure this directly
with our limited sample size, it would be interesting for further
studies to test whether such a group of MSI-high/
fibroinflammatory-high tumors correlate with increased
F. nucleatum abundance and poorer outcomes. Additionally, a
positive and negative correlation has been reported for MSS/
MSI-low and MSI-high CRCs, respectively, with higher
F. nucleatum levels and a clinically favorable increased tumor-
infiltrating lymphocyte (TIL) density [34]. Thus, the association
of increased TILs with F. nucleatum load in non-MSI-high tu-
mors may improve the disease outcomes for these patients [28].
Overall, it appears that high F. nucleatum abundance is contrib-
uting to an adverse inflammatory tumor microenvironment that
is associated with poorer outcomes, although tumor location and
molecular subtype may be important factors modifying the influ-
ence of F. nucleatum on patient outcomes.
Additionally, F. nucleatum did not appear to be a useful prog-
nostic tool for predicting individuals who may have worse sur-
vival when added to current known prognostic factors such as
tumor stage. Although, we did not have information on CRC-
specific survival, which may be more strongly related to
F. nucleatum, it is likely that most deaths in this cohort were
attributed to CRC considering the relatively short follow-up time
(median of 2.34 years). Further, larger cohort studies with infor-
mation on causes of death could examine the utility of
F. nucleatum measurement regarding CRC-specific survival
prognosis, with adequately powered analyses to assess whether
the prognostic role is greater in certain tumor subsites, molecular
subtypes, or patient subgroups.
Our study had several notable strengths and limitations.
Strengths include the use of DNA extracted from fresh-
frozen tissue, with no tissue fixation, so that we had > 99%
successful qPCR assays (based on consistent amplification of
the human PGT reference gene in all tumor and matched mu-
cosa samples), and that we assessed the prognostic utility of
F. nucleatum DNA measurement in CRC patients. However,
the survival analyses were constricted to OS so we were not
able to assess CRC-specific mortality, the cohort size was
limited for many of the subgroup analyses, and that qPCR
may not measure F. nucleatum as accurately as other ap-
proaches, such as droplet digital PCR used by Yamaoka
et al. [23]. However, qPCR is the most widely accepted and
used method of F. nucleatum measurement in other studies.
In conclusion, our study adds to the observational evidence
of an association between high abundance of F. nucleatum in
colorectal tumors and poorer survival outcomes. Additionally,
as antibiotic treatment of colon cancer xenografts in mice has
been shown to decrease F. nucleatum levels and tumor growth
[29], trials testing whether treatments aimed at reducing the
tumor F. nucleatum lead to improved clinical outcomes for
CRC patients may be warranted. Although, our study further
indicated that the utility of F. nucleatum for predicting prog-
nosis is limited, this needs to be further assessed in indepen-
dent datasets.
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